Abstract
Background The global burden of multimorbidity is increasing yet poorly understood, owing to insufficient methods available for modelling complex systems of conditions. In particular, hepatosplenic multimorbidity has been inadequately investigated.
Methods From 17 January to 16 February 2023, we examined 3186 individuals aged 5-92 years from 52 villages across Uganda within the SchistoTrack Cohort. Point-of-care B-mode ultrasound was used to assess 45 hepatosplenic conditions. Three graph learning methods for representing hepatosplenic multimorbidity were compared including graphical lasso (GL), signed distance correlations (SDC), and co-occurrence. Graph kernels were used to identify thresholds of relevant condition inter-dependencies (edges). Graph neural networks were applied to validate the quality of the graphs by assessing their predictive performance. Clinical utility was assessed through medical expert review.
Findings Multimorbidity was observed in 54·65% (1741/3186) of study participants, who exhibited two or more hepatosplenic conditions. Conditions of mildly fibrosed vessels were most frequently observed (>14% of individuals). Percentage thresholds were found to be 50·16% and 64·46% for GL and SDC, respectively, but could not be inferred for co-occurrence. Thresholded GL and SDC graphs had densities of 0·11 and 0·17, respectively. Both thresholded graphs were similar in predictive utility, although GL produced marginally higher AUCs under certain experiments. Both GL and SDC had significantly higher AUCs than co-occurrence. Numerous conditions were predicted with perfect sensitivity using both GL and SDC with graph convolutional network with five input conditions.
Interpretation The most common method for multimorbidity (co-occurrence) provided an uninformative representation of hepatosplenic conditions with respect to sparsity and predictive performance. More clinically useful graphs were computed when algorithms consisted of statistical assumptions, such as graphical lasso. Future work could apply the pipeline developed here for clinically relevant multimorbidity representations.
Funding NDPH Pump Priming Fund, John Fell Fund, Robertson Foundation, UKRI EPSRC (EP/X021793/1).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the NDPH Pump Priming Fund, John Fell Fund, Robertson Foundation Fellowship, and UKRI EPSRC (EP/X021793/1) to G.F. Chami. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data collection and use were reviewed and approved by Oxford Tropical Research Ethics Committee (OxTREC 509-21), Vector Control Division Research Ethics Committee of the Uganda Ministry of Health (VCDREC146), and Uganda National Council of Science and Technology (UNCST HS 1664ES).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Participant data are not publicly available due to data protection and ethics restrictions related to the ongoing nature of the SchistoTrack Cohort and the easily identifiable sensitive characteristics of the participants.
